NEW YORK (GenomeWeb News) – Pharmagogenomics firm DxS said today that it has signed an agreement with Amgen to market its K-RAS assay as a companion diagnostic for Amgen’s Vectibix (panitumumab) colorectal cancer therapy in the US.
 
Under the terms of the agreement, DxS’ TheraScreen K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the US Food and Drug Administration, DxS said. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.